白蛋白结合型紫杉醇联合奈达铂治疗晚期复发鼻咽癌的临床效果与安全性

Abstract
Figure/Table
References (23)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effect and safety of Albumin-bound Paclitaxel combined with Nedaplatin in the treatment of advanced recurrent nasopharyngeal carcinoma. Methods The clinical data of 78 patients who received Paclitaxel combined with Platinum for chemotherapy after relapse of advanced nasopharyngeal carcinoma in our hospital from August 2016 to June 2019 were retrospectively analyzed. Patients with Albumin-bound Paclitaxel combined with Nedaplatin for chemotherapy were used as the observation group, and patients with common Paclitaxel Injection combined with Nedaplatin for chemotherapy were used as the control group, with 39 cases in each group. After 4 cycles of chemotherapy, the short-term efficacy and incidence of adverse reactions in the two groups of patients were evaluated. Results After 4 cycles of chemotherapy, the total remission rate of the observation group was higher than that of the control group, and the difference was statistically significant (P＜0.05). There was no statistically significant difference in the incidence of hematological toxicity between the two groups (P＞0.05). In terms of non-hematological toxicity, the incidence rates of skin rash, facial flushing and peripheral neurotoxicity in the observation group were lower than those in the control group, and the differences were statistically significant (P＜0.05). There was no statistically significant difference in the incidence rate of nausea and vomiting between the two groups (P＞0.05). Conclusion Albumin-bound Paclitaxel combined with Nedaplatin in the chemotherapy of advanced recurrent nasopharyngeal carcinoma has good clinical effect, with fewer allergic reactions such as skin rash and facial flushing, and good tolerance.

Key words： Albumin-bound Paclitaxel Nasopharyngeal carcinoma Chemotherapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TONG Yan-li
	MEI Qing-hua
	ZENG Si-yu
	YANG Shui-yuan

Cite this article:

TONG Yan-li,MEI Qing-hua,ZENG Si-yu, et al. Clinical effect and safety of Albumin-bound Paclitaxel combined with Nedaplatin in the treatment of advanced recurrent nasopharyngeal carcinoma[J]. 中国当代医药, 2020, 27(19): 4-7.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I19/4

[5]	Li X，Kwon H.Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Elderly Patients with Metastatic Breast Cancer：A Meta-Analysis[J].J Clin Med，2019，8（10）：1689.
[6]	Kang Y，Shiraki E，Tsuyuki S.Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel as Neoadjuvant Chemotherapy in Breast Cancer Patients[J].Gan To Kagaku Ryoho，2019，46（9）：1427-1431.
[7]	Asahina H，Oizumi S，Takamura K，et al.A prospective phase Ⅱstudy of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease （HOT1302）[J].Lung Cancer，2019，138：65-71.
[8]	Jameson GS，Borazanci E，Babiker HM，et al.Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer：A Phase 1b/2 Pilot Clinical Trial[J].JAMA Oncol，2019，6（1）：125-132.
[9]	Specenier P.Efficacy of nab-paclitaxel in treating metastatic melanoma[J].Expert Opin Pharmacother，2019，20（5）：495-500.
[10]	Wang Y，Wang ZQ，Jiang YX，et al.A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery[J].Expert Opin Pharmacother，2016，17（12）：1585-1590.
[11]	Xiang ZZ，Liu F，Yan RN，et al.The prognostic value of volumetric reduction of the target lesions after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma[J].Head Neck，2019，41（6）：1863-1872.
[12]	Lokesh KN，Chaudhuri T，Lakshmaiah KC，et al.Induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma in adults： Results from a nonendemic region[J].Indian J Cancer，2018，55（3）：257-260.
[13]	Wu F，Wu LL，Chen GF，et al.Retrospective study on the efficacy of different chemotherapy regimens concurrently combined with intensity modulated radiation therapy in treatment of Ⅲ-Ⅳa stage nasopharyngeal carcinoma[J].Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi，2016，30（19）：1536-1539.
[14]	Loong HH，Chan AC，Wong AC.Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies[J].J Cancer，2016，7（3）：268-275.
[15]	Huang Y，Liang W，Yang Y，et al.Phase Ⅰ/ⅡDose-Finding Study of Nanoparticle Albumin-Bound Paclitaxel （nabPaclitaxel） Plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma[J].BMC Cancer，2016，16：464.
[17]	吴菲，薛蔚洁，施怡芳，等.培美曲塞联合顺铂治疗晚期非小细胞肺癌的疗效分析[J].肿瘤药学，2017，7（5）：576-580.
[18]	钱树苑，黄小冰，李睿，等.洛铂与顺铂联合吉西他滨用于晚期肺癌患者化疗的疗效比较[J].现代生物医学进展，2016，16（29）：5709-5712.
[19]	詹德超，陈梓宏，温继育，等.多西紫杉醇在局部晚期鼻咽癌奈达铂同期放化疗中联合使用的临床效果观察[J].中国医药科学，2018，8（6）：198-200.
[16]	Ke LR，Xia WX，Qiu WZ，et al.A phase Ⅱtrial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma[J].Oral Oncol，2017，70：7-13.
[20]	邱模军，汪晓梅，肖玉清.顺铂与奈达铂同期放化疗结合胎盘多肽注射液治疗晚期复发性鼻咽癌的效果分析[J].中国当代医药，2019，26（29）：58-61.
[21]	胡利兵.奈达铂联合氟尿嘧啶对食管癌患者肺功能及炎症细胞因子的影响[J].中国医学创新，2019，16（15）：113-116.
[22]	刘同欣，孙权权，陈晶，等.多西他赛联合奈达铂在局部晚期鼻咽癌中的近远期疗效、安全性及预后分析[J].中国医药导报，2019，16（23）：150-155.
[23]	Peng H，Tang LL，Chen BB，et al.Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal carcinoma：A big-data intelligence platform-based analysis[J].Oral Oncol，2018，79：40-46.
[1]	Wei KR，Zheng RS，Zhang SW，et al.Nasopharyngeal carcinoma incidence and mortality in China，2013[J].Chin J Cancer，2017，36（1）：90.
[2]	Xu T，Zhou X，Shen C，et al.Suggestions for surveillance and radiation strategy in nasopharyngeal carcinoma treated with IMRT：Based on hazard-rate and patterns of recurrence[J].Oral Oncol，2018，76：61-67.
[3]	Au E，Tan EH，Ang PT.Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer[J].Ann Oncol，1998，9（3）：327-329.
[4]	Rhomdhoni AC，Kurniawan P，Hidayati T.Correlation Between Superoxide Dismutase Serum Level Alteration with Neck Metastatic Tumor Post Cisplatin-Paclitaxel Chemotherapy Response in Nasopharyngeal Carcinoma Patients[J].Indian J Otolaryngol Head Neck Surg，2019，71（Suppl 1）：643-646.